Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
Yoon Ho Ko, Myung Ah Lee, Yeong Seon Hong, Kyung Shik Lee, Hyun Jin Park, Ie Ryung Yoo, Yeon Sil Kim, Young Kyoon Kim, Keon Hyun Jo, Young Pil Wang, Kyo Young Lee, Jin Hyoung Kang
Korean J Intern Med. 2007;22(3):178-185.   Published online 2007 Sep 30     DOI:
Citations to this article as recorded by Crossref logo
Quantitative and qualitative assessment of real world data comparative effectiveness research of systemic therapies in lung oncology: A systematic review
Bas J.M. Peters, Vivi E.M.T. Janssen, Franz M. Schramel, Ewoudt M.W. van de Garde
Cancer Epidemiology.2016; 44: 5.     CrossRef
A cross-country review of data collected on non-small cell lung cancer (NSCLC) patients in cancer registries, databases, retrospective and non-randomized prospective studies
Anna De Geer, Jennifer Eriksson, Henrik W. Finnern
Journal of Medical Economics.2013; 16(1): 134.     CrossRef
Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts
Fariba Némati, Rui Bras-Gonçalves, Jean-Jacques Fontaine, Gonzague de Pinieux, Patricia De Cremoux, Alain Chapelier, Catherine Daniel, Pierre Laurent-Puig, Alain Livartowski, Jean-Gabriel Judde, Vincent Bordier, Marie-France Poupon, Didier Decaudin
Anti-Cancer Drugs.2009; 20(10): 932.     CrossRef
Weekly Low-Dose Docetaxel for Salvage Chemotherapy in Pretreated Elderly or Poor Performance Status Patients with Non-small Cell Lung Cancer
Keun-Wook Lee, Joo Han Lim, Jee Hyun Kim, Choon-Taek Lee, Jong Seok Lee
Journal of Korean Medical Science.2008; 23(6): 992.     CrossRef